Eli Lilly and Co. Plans to Build Four New Sites in the U.S.

Source: (Photo by Victor J. Blue/Bloomberg via Getty Images.)

INDIANAPOLIS — Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.  

Eli Lilly plans to add four new sites so they can focus on active ingredients, which are key ingredients in drugs.  

However, Lilly did not say where the sites will be, but they said they plan to establish 3,000 jobs for employees with good skills and experience, as well as 10,000 construction jobs during this process.  

Since 2020, Eli Lilly marked about $50 billion in spending to keep up with the increase in demand for its GLP-1 medications, which are Mounjaro for diabetes and Zepbound for weight loss. Eli Lilly CEO Dave Ricks says that even with both Eli Lilly and Novo Nordisk (NVO) increasing production, there is more demand than supply by either of those two companies.  

Most APIs are made in outside of the United States, which has gained attention in recent years due to pandemic-related supply chain disruptions. Right now, only about 4% of APIs are made in the United States, while China and India have control of the global production, supplying over 60% of APIs in some cases.